rewirebio.iobenchmarks
Configuration

DELFI 2019 internally cross-validated cancer detection tested configuration

DELFI 2019 internally cross-validated cancer detection tested configuration; bounded primary-source candidate.

1 evaluation · 1 result

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for DELFI 2019 internally cross-validated cancer detection tested configuration. Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluations and results

1 evaluation · 1 result. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: DELFI 2019 internally cross-validated cancer detection tested configurationProtocol: DELFI 2019 internally cross-validated cancer detection protocol
Dataset: DELFI 2019 internally cross-validated cancer detection cohort
73% Sensitivity at 98% specificity
percent · higher

Uncertainty: 95% CI 67 to 79

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

DELFI 2019 internally cross-validated cancer detection

amp-20261007-ctdna-fragmentomics-protocol

Aggregation: Not reported

Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 · PMC6774252 Table 1 T1 Cancer row / 98% specificity columns; Results P15; Methods P34; Extended Data Fig. 7 F11.

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this configuration

How it works, versions and access

Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID amp-20261007-ctdna-fragmentomics-configuration.

Related records

How to cite

DELFI 2019 internally cross-validated cancer detection tested configuration. Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/amp-20261007-ctdna-fragmentomics-configuration/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction